Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab
Withdrawn before enrolling
Conditions studied: Chronic Rhinosinusitis (Diagnosis), Asthma, Nasal Polyps
In brief
The primary objective of this research is to monitor chronic rhinosinusitis (CRS) symptoms in asthma patients who are undergoing treatment with reslizumab. A secondary objective is to explore whether there are sub-populations that appear to benefit or not benefit from reslizumab in terms of their CRS symptoms.
Key facts
- Study ID
- NCT03369574
- Run by
- University of Rochester
- People needed
- 0
- Starts
- 2017-11-14
- Expected to finish
- 2018-10-19
- Last updated by the study team
- 2019-11-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age is 18 years or older
- Physician diagnosis of poorly controlled moderate to severe asthma despite typical medical therapy with an eosinophilic phenotype (defined by blood eosinophil count of 150 µL or greater within 6 weeks of enrollment)
- Initiating or undergoing reslizumab therapy (Reslizumab - Patient Information listed in Appendix 1 for reference)
- Physician diagnosis of chronic rhinosinusitis with nasal polyposis
- Able to understand and willing to provide informed consent
- Able to complete standard of care English-language questionnaires
You may not qualify if…
- Current smokers
- Significant uncontrolled medical conditions
- Ongoing malignancy or history of cancer in remission for less than 12 months
- Subjects who had received immunosuppressive medications within 3 months of enrollment
Where it is running
- University of Rochester Department of Otolaryngology Head and Neck Surgery — Rochester, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.